Eisai and Biogen Alzheimer's drug lecanemab receives approval from FDA
Eisai and Biogen's drug, sold under the brand name Leqembi, is the first amyloid-targeting medication to pass the FDA's full review.
Stay updated with breaking news from Ivan Cheung. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Eisai and Biogen's drug, sold under the brand name Leqembi, is the first amyloid-targeting medication to pass the FDA's full review.
(CNN) — The US Food and Drug Administration is expected to decide on Thursday whether to grant traditional approval to the Alzheimer’s drug Leqembi, the first medicine proven to slow
The US Food and Drug Administration is expected to decide on Thursday whether to grant traditional approval to the Alzheimer’s drug Leqembi, the first medicine proven to slow the course
The F.D.A. gave full approval to the drug, but added a black-box warning about safety risks. Medicare said it would cover most of the high cost.
The Food and Drug Administration has approved the first drug proven to slow the progress of Alzheimer's Disease on Thursday.